The Ledger

UnitedHealth Group’s chief financial officer just told Wall Street the insurer’s Medicare Advantage turnaround is beating plan, even as the company confirmed it will end 2026 with up to 1.1 million fewer Medicare Advantage members than it started with. Speaking at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, UnitedHealthcare Chief Financial Officer Wayne DeVeydt said Medicare Advantage margins are now tracking to the upper half of the company’s 2 to 4 percent target range for 2026, an improvement on earlier guidance, and that the insurer expects to be “very competitive in terms of our pricing next year” as it prepares 2027 bids, adding “we think we’ll be well-positioned for 2027.” UnitedHealthcare’s Medicare Advantage enrollment fell to about 7.6 million members in the second quarter of 2026 from 8.4 million at the end of 2025, and the company is weighing an exit from 34 additional counties across 12 states, affecting roughly 20,000 members, on top of the 109-county pullback it had already disclosed. Elevance Health and Centene struck a similar note at the same conference; Centene Chief Executive Officer Sarah London said the insurer plans to “further simplify” its Medicare Advantage footprint for 2027, with both companies emphasizing retention of dual-eligible members over broad enrollment growth, the same strategic shift this run flagged from earnings-call disclosures on September 8. Confidence: High on the company-specific figures and quotes, drawn from named executives speaking at a public investor conference and reported directly by trade press. Sources: UnitedHealthcare expects to be ‘very competitive’ in Medicare Advantage next year, CFO says, Healthcare Dive, UnitedHealthcare at Wells Fargo conference: turnaround gains traction, Investing.com.

557: that is how many information-technology jobs Trinity Health, a Catholic nonprofit hospital system based in Livonia, Michigan, is eliminating as it hands its IT support desk to an outside vendor. A Worker Adjustment and Retraining Notification (WARN) notice shows the layoffs running from October 25 through November 29, 2026, with the single largest category, Service Desk Support I, accounting for 49 of the eliminated roles; affected positions span service desk support, database administration, network security and applications engineering. Trinity Health, which operates hospitals and other programs across 23 states, said in June it was moving IT support to a technology partner, stating “a partner whose core business is technology support gives us access to specialized expertise and innovation at the speed and scale health care now requires while strengthening service reliability”; the company said patient-facing roles are not affected by this round of cuts. A class-action firm, Strauss Borrelli PLLC, has separately opened an investigation into whether Trinity Health gave the required 60 days of advance written notice under the WARN Act. Confidence: High. This run reviewed local television and wire reporting citing the company’s own WARN filing and statement directly. Sources: Trinity Health laying off 557 workers in Livonia after outsourcing IT services, WXYZ, Trinity Health in Livonia to lay off 557 employees starting in October, primarily in IT support, Michigan Advance.

380 million dollars: that is the fresh private placement a preclinical Alzheimer’s drug developer banked the same week it bought its way onto the Nasdaq through a reverse merger. Korsana Biosciences completed its merger with the public shell Cyclerion Therapeutics on September 8, 2026, with Cyclerion shareholders receiving approximately 0.2074 shares of the combined company per share held, adjusted for a 1-for-7 reverse stock split executed ahead of the deal; alongside the merger, Korsana closed a 380 million dollar private placement of common stock and pre-funded warrants from investors including Fairmount, Venrock Healthcare Capital Partners and General Atlantic. Combined with existing cash, the company now holds approximately 475 million dollars, which it says funds operations into 2029; shares began trading on the Nasdaq Capital Market on September 9, 2026 under the ticker KRSA. Korsana’s lead candidate, KRSA-028, is a shuttled antibody targeting amyloid beta for Alzheimer’s disease, with Phase 1 data expected in mid-2027 and proof-of-concept data in late 2027 or early 2028. Confidence: High. This run reviewed the company’s own closing announcement directly. Sources: Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million, GlobeNewswire.

Two healthcare data companies changed hands within a day of each other this week, a sign of where dealmakers see value even as hospital and clinic M&A slows. Eir Partners, a Miami-based private equity firm that invests 40 million to 150 million dollars or more in healthcare technology, announced September 9, 2026 that it acquired Accumulus Technologies, a cloud SaaS platform used by more than 75 global regulatory authorities to streamline drug development and approval workflows and a 2025 spinout of the nonprofit Accumulus Synergy; terms were not disclosed. The same day, H1, an AI-powered provider-data platform used by 85 percent of the top 20 pharmaceutical companies and 9 of the top 10 health plans, announced it acquired Defacto Health, a provider-network intelligence firm that helps health plans check directory accuracy, also for an undisclosed sum. A September 8 sector-trends note from a law firm tracking the space observed that healthcare and life-sciences dealmaking is bifurcating, with “capital and preparation concentrating in product and platform businesses, while care delivery is transacting less, later, and more often out of distress than out of ambition,” a framing this week’s data deals fit squarely. Confidence: High on the deal facts, drawn from the companies’ own announcements. Medium on the broader trend framing, drawn from a single secondary analysis. Sources: Accumulus Technologies Announces Acquisition by Eir Partners to Accelerate Next Phase of Growth, GlobeNewswire, H1 Acquires Defacto Health to Strengthen Provider Network Intelligence, GlobeNewswire, Healthcare & Life Sciences Sector: Trends and Upcoming Deals, National Law Review.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Cyclerion Therapeutics (reverse merger into Korsana Biosciences)	Korsana Biosciences; $380 million private placement led by Fairmount, Venrock Healthcare Capital Partners, General Atlantic	Biopharma, neurodegenerative disease	$380 million private placement; merger completed September 8, 2026, trading began September 9 as Nasdaq: KRSA	GlobeNewswire
Accumulus Technologies	Eir Partners	Life sciences regulatory technology, SaaS	Undisclosed; announced September 9, 2026	GlobeNewswire
Defacto Health	H1	Healthcare data, provider network intelligence	Undisclosed; announced September 9, 2026	GlobeNewswire

This run’s scan of FTC and DOJ merger actions and state transaction-review dockets found no new healthcare antitrust complaints or consent orders in the last 24 to 48 hours. A frontier check on dental service organization consolidation (Group Dentistry Now, Becker’s Dental Review) and on healthcare ransomware disclosures (HealthcareInfoSecurity), two Ledger branches not touched in the last three issues, found ongoing coverage but no newly dated transaction or breach disclosure inside this window. An open-ended scan surfaced the two same-day health-data acquisitions covered above as the window’s most consequential business signal outside the biotech and payer stories.